Founded out of research at the University of Cambridge, Nuclera is a biotech company developing protein-printing technologies to make proteins more accessible to everyone. In doing so, the bioprinter company enables life science researchers to accelerate breakthrough improvements in human health due to better access to biomolecules.
The company is somewhat revolutionary, seeing as developing proteins has long been a time-consuming and complicated process. Rather than taking weeks, months, or years, Nuclera’s eProtein desktop bioprinting technology does so in hours.
Trust in the product is marked by substantial funding between 2018 and 2022. Its extended Series C round, completed in 2026, is being used to ramp up the development of its eProtein Discovery system, maximising the impact of the proteins it prints.
Freddie
Company Specialist at Welcome to the Jungle